Balamuthia mandrillaris: role of galactose in encystment and identification of potential inhibitory targets.
Balamuthia mandrillaris is a causative agent of granulomatous encephalitis that almost always proves fatal. A major concern during the course of therapy is that B. mandrillaris can transform into cysts. Cysts are highly resistant to physical and chemical conditions and present a problem in successful antimicrobial chemotherapy. However, the underlying mechanisms of B. mandrillaris transformation into cysts are not known. In this study, we examined the effects of exogenous sugars on B. mandrillaris encystment. The findings revealed that free exogenous galactose, but not other sugars, enhanced parasite differentiation into cysts, and apparently a galactose-binding protein is involved in B. mandrillaris encystment. Cytoskeletal re-arrangements and phosphatidylinositol 3-kinase (PI3K)-mediated pathways are involved in B. mandrillaris encystment based on inhibitor studies. Dual functionality of galactose-binding protein in B. mandrillaris pathogenesis and encystment is discussed further.
Siddiqui
Ruqaiyyah
R
School of Biological and Chemical Sciences, Birkbeck College, University of London, London, England, UK.
Jarroll
Edward L
EL
Khan
Naveed Ahmed
NA
D000577:Amides / Q000494:pharmacology; D056894:Amoebozoa / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000098:blood supply / Q000166:cytology; D002135:Calcium-Binding Proteins / Q000502:physiology*; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D015638:Cytochalasin D / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects / Q000502:physiology; D042783:Endothelial Cells / Q000469:parasitology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005690:Galactose / Q000378:metabolism / Q000494:pharmacology*; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D009004:Monosaccharide Transport Proteins / Q000502:physiology*; D009025:Morpholines / Q000494:pharmacology; D033902:Periplasmic Binding Proteins / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014638:Vanadates / Q000494:pharmacology; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors
D000577:Amides; D002135:Calcium-Binding Proteins; D002867:Chromones; D015638:Cytochalasin D; D004791:Enzyme Inhibitors; D005690:Galactose; D019833:Genistein; D009004:Monosaccharide Transport Proteins; D009025:Morpholines; D033902:Periplasmic Binding Proteins; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D017027:Protein Tyrosine Phosphatases; D011505:Protein-Tyrosine Kinases; D011725:Pyridines; D014638:Vanadates; D054460:rho-Associated Kinases; C023550:galactose-binding protein; C108830:Y 27632; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one